ECSP10010701A - Formulación farmaceutica de eprosartan - Google Patents

Formulación farmaceutica de eprosartan

Info

Publication number
ECSP10010701A
ECSP10010701A EC2010010701A ECSP10010701A ECSP10010701A EC SP10010701 A ECSP10010701 A EC SP10010701A EC 2010010701 A EC2010010701 A EC 2010010701A EC SP10010701 A ECSP10010701 A EC SP10010701A EC SP10010701 A ECSP10010701 A EC SP10010701A
Authority
EC
Ecuador
Prior art keywords
eprosartan
dose
administered
compound
pharmaceutical formulation
Prior art date
Application number
EC2010010701A
Other languages
English (en)
Inventor
Paulus A J Link
Der Hulst Marcellus M Van
Gerhard-Wihelm Bielenberg
Den Akker Cornelis R Van
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of ECSP10010701A publication Critical patent/ECSP10010701A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La invención descripta se refiere a un método de tratamiento de un trastorno modulado mediante el bloqueo de los receptores de angiotensina II (AII), y particularmente seleccionados del grupo que consiste de hipertensión, falla cardíaca congestiva, falla renal, y combinaciones de los mismos, administrando a un sujeto en necesidad del mismo una dosis efectiva de un compuesto de eprosartan. Con referencia a la Dosis Diaria Efectiva Recomendada de 600 mg, calculada en base a eprosartan administrada en forma de mesilato de eprosartan, ahora se ha hallado que puede ser administrada una dosis menor de eprosartan cuando el compuesto de eprosartan es eprosartan ácido. Esta dosis está en el rango de desde 410 a 490 mg, lo más preferiblemente aproximadamente 450 mg.
EC2010010701A 2008-07-11 2010-12-21 Formulación farmaceutica de eprosartan ECSP10010701A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8006708P 2008-07-11 2008-07-11
EP08160211 2008-07-11

Publications (1)

Publication Number Publication Date
ECSP10010701A true ECSP10010701A (es) 2011-01-31

Family

ID=39731507

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010701A ECSP10010701A (es) 2008-07-11 2010-12-21 Formulación farmaceutica de eprosartan

Country Status (21)

Country Link
US (2) US20100010062A1 (es)
EP (1) EP2317987B1 (es)
JP (1) JP2011527314A (es)
KR (1) KR20110031226A (es)
CN (1) CN102088961A (es)
AR (1) AR072477A1 (es)
AU (1) AU2009268044A1 (es)
BR (1) BRPI0915455A2 (es)
CA (1) CA2730008A1 (es)
CO (1) CO6331424A2 (es)
DO (1) DOP2011000011A (es)
EA (1) EA201170182A1 (es)
EC (1) ECSP10010701A (es)
IL (1) IL210001A0 (es)
MX (1) MX2011000349A (es)
NZ (1) NZ589904A (es)
PE (1) PE20110412A1 (es)
TW (1) TW201006826A (es)
UA (1) UA100434C2 (es)
WO (1) WO2010003996A1 (es)
ZA (1) ZA201100223B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5910311B2 (ja) * 2012-05-23 2016-04-27 ニプロ株式会社 医薬錠剤およびその製造方法
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034103T2 (de) * 1989-06-14 2004-07-15 Smithkline Beecham Corp. Imidazoalkensäure
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
JP4880118B2 (ja) * 1997-11-17 2012-02-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 薬物高充填性の即時放出性または放出を修飾した経口用投与処方およびその製法
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
IL140905A0 (en) * 1998-07-20 2002-02-10 Smithkline Beecham Corp Bioenhanced formulations comprising eprosartan in oral solid dosage form
DE04801160T1 (de) * 2003-12-01 2007-08-09 Lifecycle Pharma A/S Pharmazeutische zusammensetzungen mit lercanidipin
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
CA2628955A1 (en) * 2005-11-07 2007-05-18 Edward S. Wilson Compositions of stabilized ramipril in combination with another active agent

Also Published As

Publication number Publication date
MX2011000349A (es) 2011-02-22
EP2317987A1 (en) 2011-05-11
WO2010003996A1 (en) 2010-01-14
NZ589904A (en) 2012-08-31
UA100434C2 (en) 2012-12-25
BRPI0915455A2 (pt) 2017-06-27
JP2011527314A (ja) 2011-10-27
DOP2011000011A (es) 2011-01-31
CN102088961A (zh) 2011-06-08
IL210001A0 (en) 2011-02-28
KR20110031226A (ko) 2011-03-24
ZA201100223B (en) 2011-10-26
PE20110412A1 (es) 2011-07-04
EA201170182A1 (ru) 2011-08-30
TW201006826A (en) 2010-02-16
EP2317987B1 (en) 2014-04-23
CO6331424A2 (es) 2011-10-20
US20100010062A1 (en) 2010-01-14
US20120302555A1 (en) 2012-11-29
CA2730008A1 (en) 2010-01-14
AR072477A1 (es) 2010-09-01
AU2009268044A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CL2021001288A1 (es) Heterociclos funcionalizados como agentes antivirales
EA201690033A3 (ru) Морфинановые соединения
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CL2012002356A1 (es) Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras.
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
ECSP055935A (es) Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension
CO6761298A2 (es) Combinaciones que comprenden antipsicóticos atípocos y antagonistas taar1
NI201000053A (es) Trans-clomifeno para el síndrome metabólico.
SV2011003907A (es) Composiciones antimicrobianas
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
PH12014502331A1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
EA201170512A1 (ru) Композиция для перорального введения
CR20110209A (es) Composición farmacéutica sólida
MA31706B1 (fr) Formulations galéniques de composés organiques
MX2009012472A (es) Combinacion que comprende acido pirrolidona-5-carboxilico y por lo menos un compuesto de citrulina, arginina y asparragina, y su uso en el tratamiento de dermatitis atopica.
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
PA8784901A1 (es) Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
ECSP10010701A (es) Formulación farmaceutica de eprosartan
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof
CU20110232A7 (es) Inyección de diacetato de ipamorelin y soluciones de la infusión
CR20110024A (es) Formulación farmáceutica de eprosartan